Cite
HARVARD Citation
Herzog, T. et al. (n.d.). 2022-RA-687-ESGO ARTISTRY-7: phase 3, multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68). International journal of gynecological cancer. pp. A255-A256. [Online].